Clinical data | |
---|---|
Routes of administration | Oral, intranasal |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 70% (oral) |
Protein binding | >99% |
Metabolism | Hepatic |
Excretion | <1% excreted unchanged in urine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.208.947 |
Chemical and physical data | |
Formula | C18H18F3N3O3 |
Molar mass | 381.355 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Pleconaril (Picovir[1]) is an antiviral drug that was being developed by Schering-Plough for prevention of asthma exacerbations and common cold symptoms in patients exposed to picornavirus respiratory infections.[2] Pleconaril, administered either orally or intranasally, is active against viruses in the Picornaviridae family, including Enterovirus[3] and Rhinovirus.[4] It has shown useful activity against the dangerous enterovirus D68.[5]